Having qualified assays and appropriate cGMPs in place is crucial to support product quality when bringing a gene therapy product into late-phase studies, the US FDA says. This week, the US Food and Drug Administration (FDA) hosted the first in a series of virtual town halls aimed at engaging with product development stakeholders and researchers to discuss topics related to advanced therapies. The event run by the Office of Tissues and Advanced Therapies (OTAT) – soon to become the Office…